A rare case of spontaneous renal cholesterol crystallization embolism

0
0
0

A rare case of spontaneous renal cholesterol crystallization embolism

Cholesterol is essential for our bodies—but when tiny crystals of it break loose and block small blood vessels, it can cause serious harm. One of the most vulnerable organs? The kidneys. Most often, this condition—called cholesterol crystal embolism (CCE)—follows medical procedures like heart catheterization or surgery. But sometimes, it strikes without warning. A 2019 study in the Chinese Medical Journal details just such a case: a 78-year-old man with no obvious triggers who developed spontaneous renal CCE—and ultimately regained healthy kidney function after targeted care.

What is cholesterol crystal embolism (CCE)?

CCE is a systemic disease where cholesterol crystals from hardened artery plaques (atherosclerosis) break off and lodge in small blood vessels. This blocks blood flow to organs like the kidneys, skin, or gut. The kidneys are the most common target: about half of CCE patients develop renal involvement. While most cases link to medical procedures (like stenting or bypass surgery), “spontaneous” CCE occurs when crystals embolize without any obvious trigger—making it harder to diagnose.

The patient’s story: A slow decline, no classic signs

The patient was a 78-year-old man with a 10-year history of diabetes (managed with pills) and 5 years of hypertension (treated with amlodipine and valsartan). Two months before hospitalization, he developed protein in his urine (proteinuria) and was put on a low-protein diet. But his kidney function worsened: his serum creatinine (a key marker of kidney health) rose to 2.26 mg/dL—well above the normal range (0.6–1.2 mg/dL for men). By May 2014, he had acute kidney injury and needed hospital care.

Notably, he had no classic CCE symptoms: no blue toes, no lacy skin discoloration (livedo reticularis), no finger/toe gangrene. A physical exam was normal. Blood tests showed mild anemia (hemoglobin 103 g/L), slightly elevated eosinophils (a type of immune cell linked to inflammation), and normal cholesterol levels. Ultrasound found plaque in his carotid and leg arteries—but no kidney abnormalities on CT scans.

The diagnostic breakthrough: A kidney biopsy

Since his symptoms weren’t “textbook,” doctors ordered a kidney biopsy. The results were clear: two large kidney arteries were almost completely blocked, and needle-like “fissures” (left behind when cholesterol crystals dissolve during biopsy processing) were visible. Immune tests showed a small amount of IgM protein in some arteries—clues that inflammation was present.

This confirmed the diagnosis: spontaneous renal CCE nephropathy. Unlike most CCE cases, there was no prior procedure to blame. The crystals had come from his existing arterial plaque, which had ruptured on its own.

Treatment: Controlling risks and supporting kidneys

The goal of care was twofold: (1) prevent more cholesterol crystals from breaking loose and (2) support kidney function. The team adjusted his medications first:

  • Diabetes management: Switched from oral pills to insulin to get his blood sugar under control (from 8.9 mmol/L at diagnosis to 5.6 mmol/L in 135 days).
  • Hypertension control: Prescribed clonidine, arotinolol, and benidipine—lowering his blood pressure from 160/95 mmHg to 110/70 mmHg.
  • Plaque stabilization: Even though his cholesterol was normal, he took atorvastatin (Lipitor) to strengthen his artery walls and reduce the risk of more crystals breaking off.
  • Kidney support: A high-quality low-protein diet and ketosteril (a supplement for chronic kidney disease) helped ease the load on his kidneys. Traditional Chinese medicine (Corbrin) was also used for supportive care.

The outcome: Slow but steady recovery

At first, his kidney function worsened: his serum creatinine peaked at 3.50 mg/dL (a sign of severe kidney stress) in September 2014. But over the next three years, his kidneys bounced back. By September 2017—three years after diagnosis—his creatinine had dropped to 0.90 mg/dL, well within the normal range. Today, he enjoys a good quality of life.

Why this case matters: Diagnosis and hope

CCE is tricky to spot because its symptoms are often vague—like fatigue, proteinuria, or rising creatinine. Classic signs (blue toes, skin changes) are missing in up to 40% of cases, as they were here. The only sure way to diagnose it is through a biopsy (of the kidney, skin, or gut) that finds cholesterol “clefts” in blood vessels.

For this patient, the biopsy was life-changing. Without it, his condition might have been misdiagnosed as typical chronic kidney disease (CKD) from diabetes or hypertension. Instead, the team could tailor his care to target the root cause: unstable plaque and embolized cholesterol crystals.

Key takeaways for patients and providers

  • If you have kidney issues with no clear cause: Ask about CCE—especially if you have atherosclerosis (plaque in arteries).
  • Biopsies save lives: For non-classic cases, a biopsy is the gold standard for diagnosis.
  • Even severe kidney injury can reverse: Only 21–28% of CCE patients regain kidney function, but this case shows it’s possible with careful management.

This study was conducted by Ling-Yun Chen (Shanghai Electric Power Hospital), Yan-Ping Huang, Shao-Jun Liu (Huashan Hospital, Fudan University), and Pei-Jyu Mao (Tongren Hospital, Shanghai Jiao Tong University School of Medicine). It was published in the Chinese Medical Journal in 2019.

References:

  1. Scolari F, Ravani P. Atheroembolic renal disease. Lancet 2010;375:1650–1660.
  2. Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis 2000;36:1089–1109.
  3. Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation 2007;116:298–304.
  4. Yang XL, Yu HJ, Zhu HY, et al. Potential value of datura stramonium agglutinin-recognized glycopatterns in urinary protein on differential diagnosis of diabetic nephropathy and nondiabetic renal disease. Chin Med J (Engl) 2018;131:180–187.
  5. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 2010;122:631–641.
  6. Quinones A, Saric M. The cholesterol emboli syndrome in atherosclerosis. Curr Atheroscler Rep 2013;15:315.
  7. Abela GS, Vedre A, Janoudi A, et al. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol 2011;107:1710–1717.
  8. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 1999;33:840–850.
  9. Shames ML, Rubin BG, Sanchez LA, et al. Treatment of embolizing arterial lesions with endoluminally placed stent grafts. Ann Vasc Surg 2002;16:608–612.
  10. Theriault J, Agharazzi M, Dumont M, et al. Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases. Nephron Clin Pract 2003;94:c11–c18.

doi.org/10.1097/CM9.0000000000000078

Was this helpful?

0 / 0